New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

about

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

Item

http://www.wikidata.org/entity/Q35703714

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@ast

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@en

type

Item

label

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@ast

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@en

prefLabel

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@ast

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@en

P1476

New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.

@en

P2093

Peter Reimer

http://www.w3.org/2001/XMLSchema#string

P2860

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

P304

145-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S85351

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26082661

http://www.w3.org/2001/XMLSchema#string

P932

4461120

http://www.w3.org/2001/XMLSchema#string